BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Target
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $57 price target.
Share
Why It Matters
A research analyst still thinks VTVT is a good investment choice. Watch if the company hits goals and if other analysts agree too.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.